Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Eiger BioPharmaceuticals, Inc is a biotechnology business based in the US. Eiger BioPharmaceuticals shares (EIGR) are listed on the NASDAQ and all prices are listed in US Dollars. Eiger BioPharmaceuticals employs 29 staff and has a market cap (total outstanding shares value) of USD$335.4 million.
|Latest market close||USD$8.76|
|52-week range||USD$4.55 - USD$15.6|
|50-day moving average||USD$9.76|
|200-day moving average||USD$9.9816|
|Wall St. target price||USD$31.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.649|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||-24.22%|
|1 month (2020-12-18)||-10.15%|
|3 months (2020-10-16)||-15.61%|
|6 months (2020-07-17)||-6.41%|
|1 year (2020-01-17)||-37.83%|
|2 years (2019-01-18)||-36.57%|
|3 years (2018-01-18)||8.9|
|5 years (2016-01-15)||661.74%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-29.11%|
|Return on equity TTM||-76.75%|
|Market capitalisation||USD$335.4 million|
TTM: trailing 12 months
There are currently 1.5 million Eiger BioPharmaceuticals shares held short by investors – that's known as Eiger BioPharmaceuticals's "short interest". This figure is 14.9% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Eiger BioPharmaceuticals shares can be evaluated.
Eiger BioPharmaceuticals's "short interest ratio" (SIR) is the quantity of Eiger BioPharmaceuticals shares currently shorted divided by the average quantity of Eiger BioPharmaceuticals shares traded daily (recently around 686032.43243243). Eiger BioPharmaceuticals's SIR currently stands at 2.22. In other words for every 100,000 Eiger BioPharmaceuticals shares traded daily on the market, roughly 2220 shares are currently held short.
However Eiger BioPharmaceuticals's short interest can also be evaluated against the total number of Eiger BioPharmaceuticals shares, or, against the total number of tradable Eiger BioPharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eiger BioPharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Eiger BioPharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0476% of the tradable shares (for every 100,000 tradable Eiger BioPharmaceuticals shares, roughly 48 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eiger BioPharmaceuticals.
Find out more about how you can short Eiger BioPharmaceuticals stock.
We're not expecting Eiger BioPharmaceuticals to pay a dividend over the next 12 months.
Eiger BioPharmaceuticals's shares were split on a 1:15 basis on 23 March 2016. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Eiger BioPharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Eiger BioPharmaceuticals shares which in turn could have impacted Eiger BioPharmaceuticals's share price.
Over the last 12 months, Eiger BioPharmaceuticals's shares have ranged in value from as little as $4.55 up to $15.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eiger BioPharmaceuticals's is 1.2951. This would suggest that Eiger BioPharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.